Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.58 USD | +10.58% | -15.98% | 0.00% |
01:59pm | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.72B | |
+30.12% | 48.16B | |
-0.82% | 41.73B | |
+42.66% | 41.03B | |
-5.26% | 28.77B | |
+10.15% | 25.59B | |
-22.65% | 18.96B | |
+9.12% | 12.92B | |
+29.25% | 12.03B | |
-1.98% | 11.77B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55